---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-042354"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:33:00.527822+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CVRx reports preliminary Q1 2026 revenue $14.7-14.8M, +20% YoY; gross margin 87%

## Summary
- Revenue expected $14.7-14.8M vs $12.3M in Q1 2025, ~20% growth.
- Gross margin ~87% (84% in Q1 2025); operating expenses ~$25M vs $23.7M.
- Cash and equivalents ~$72.3M at Mar 31, 2026; active implanting centers 257 (+5 vs Dec 2025).
- Medicare Advantage 30-day approval rate rose to 50% in Jan-Feb 2026 vs 44% in 2025 and 31% in 2024.
- First site activated in BENEFIT-HF trial on Mar 31; enrollment expected Q2 2026.

## SEC filing metadata
- accession: 0001104659-26-042354
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465926042354/0001104659-26-042354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465926042354/tm2611335d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-042354
- JSON: https://secwatch.observer/filing/0001104659-26-042354.json
- Plain text: https://secwatch.observer/filing/0001104659-26-042354.txt

## Key facts
- Earnings Releases
  CVRx, Inc. reported first quarter ended March 31, 2026 results: revenue $14.7 million to $14.8 million.
  - Period: first quarter ended March 31, 2026
  - Revenue: $14.7 million to $14.8 million
  - Result: preliminary results
  source text: EXHIBIT 99.1 Exhibit 99.1 CVRx Reports Preliminary First Quarter 2026 Financial Results · Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 · Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465926042354/0001104659-26-042354-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.